Suven features as one of ‘Best Under A Billion’ companies by Forbes Asia

07 Oct 2014 Evaluate

Suven Life Sciences has been selected as one of the ‘Best Under A Billion’ companies by Forbes Asia 2014. Forbes Asia’s ‘Best Under A Billion’ list highlights 200 of the best small and midsized listed companies in Asia Pacific with annual revenue under $1 billion. To qualify for the selection, companies must have revenue between $5 million and $1 billion, positive net income and be publicly traded for at least a year.

From a universe of 17,000 companies, qualified candidates are screened on sales growth, earnings growth and return on equity. The result is a final list featuring 200 exceptional small and midsized companies from Asia Pacific.

In recognition of the achievement of these 200 ‘Best Under A Billion’ Companies, Forbes Asia is organizing an Award Ceremony and the company will receive this award on December 09, 2014 in Bangkok, Thailand.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

166.20 -2.25 (-1.34%)
18-Dec-2025 11:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.20
Dr. Reddys Lab 1278.20
Cipla 1507.40
Zydus Lifesciences 916.75
Lupin 2124.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×